Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 8Gastrointestinal 4Gynecologic 2Tumor-Agnostic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Pediatric Solid Tumor 1

Interventions

pembrolizumab 30Injections 26Pemetrexed 15Interviews as Topic 15tislelizumab 13Specimen Handling 13Carboplatin 13Cisplatin 12Nivolumab 11atezolizumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Bevacizumab 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Platinum 6Paclitaxel 6Leucovorin 6Ipilimumab 6Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Testing × Other solid neoplasm × 90 days × Clear all
NCT02520713 2026-04-28

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

Dana-Farber Cancer Institute

Active not recruiting
825 enrolled
Other solid neoplasm

Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡